%0 Journal Article
%A Bochtler, Tilmann
%A Reiling, Anna
%A Endris, Volker
%A Hielscher, Thomas
%A Volckmar, Anna-Lena
%A Neumann, Olaf
%A Kirchner, Martina
%A Budczies, Jan
%A Heukamp, Lukas C
%A Leichsenring, Jonas
%A Allgäuer, Michael
%A Kazdal, Daniel
%A Löffler, Harald
%A Weichert, Wilko
%A Schirmacher, Peter
%A Stenzinger, Albrecht
%A Krämer, Alwin
%T Integrated clinico-molecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
%J International journal of cancer
%V 146
%N 11
%@ 1097-0215
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2020-00267
%P 3053-3064
%D 2020
%Z 2020 Jun 1;146(11):3053-3064#EA:A360#LA:A360#
%X Cancer of unknown primary (CUP) denotes a malignancy with histologically confirmed metastatic spread while the primary tumor remains elusive. Here, we address prognostic and therapeutic implications of mutations and copy number variations (CNVs) detected in tumor tissue in the context of a comprehensive clinical risk assessment. Targeted panel sequencing was performed in 252 CUP patients. 71.8
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31970771
%R 10.1002/ijc.32882
%U https://inrepo02.dkfz.de/record/153234